NasdaqGS - Nasdaq Real Time Price • USD
Natera, Inc. (NTRA)
As of 11:48 AM EDT. Market Open.
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 15 | 14 | 16 | 16 |
| Avg. Estimate | -0.7 | -0.63 | -2.31 | -1.19 |
| Low Estimate | -0.78 | -0.7 | -2.52 | -1.6 |
| High Estimate | -0.65 | -0.55 | -2.02 | -0.57 |
| Year Ago EPS | -1.23 | -0.97 | -3.78 | -2.31 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 14 | 14 | 16 | 16 |
| Avg. Estimate | 316.31M | 328.27M | 1.34B | 1.58B |
| Low Estimate | 304.9M | 318.29M | 1.33B | 1.5B |
| High Estimate | 329M | 334.69M | 1.36B | 1.75B |
| Year Ago Sales | 227.67M | 242.06M | 1.08B | 1.34B |
| Sales Growth (year/est) | 38.90% | 35.60% | 23.90% | 17.90% |
Earnings History
| CURRENCY IN USD | 3/31/2023 | 6/30/2023 | 9/30/2023 | 12/31/2023 |
|---|---|---|---|---|
| EPS Est. | -1.15 | -1.09 | -0.96 | -0.73 |
| EPS Actual | -1.23 | -0.97 | -0.95 | -0.64 |
| Difference | -0.08 | 0.12 | 0.01 | 0.09 |
| Surprise % | -7.00% | 11.00% | 1.00% | 12.30% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.7 | -0.63 | -2.31 | -1.19 |
| 7 Days Ago | -0.7 | -0.62 | -2.32 | -1.2 |
| 30 Days Ago | -0.71 | -0.62 | -2.34 | -1.21 |
| 60 Days Ago | -0.75 | -0.7 | -2.62 | -1.37 |
| 90 Days Ago | -0.75 | -0.7 | -2.63 | -1.42 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Mar 2024) | Next Qtr. (Jun 2024) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | 2 | 2 |
| Up Last 30 Days | 2 | -- | 5 | 5 |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | 1 | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | NTRA | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 43.10% | -- | -- | 1.50% |
| Next Qtr. | 35.10% | -- | -- | 12.10% |
| Current Year | 38.90% | -- | -- | 4.40% |
| Next Year | 48.50% | -- | -- | 13.20% |
| Next 5 Years (per annum) | -- | -- | -- | 10.97% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Upgrades & Downgrades
| Maintains | Goldman Sachs: Buy to Buy | 4/15/2024 |
| Upgrade | Bernstein: Market Perform to Outperform | 4/5/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 3/6/2024 |
| Maintains | Goldman Sachs: Buy to Buy | 2/29/2024 |
| Maintains | Canaccord Genuity: Buy to Buy | 2/29/2024 |
| Downgrade | Raymond James: Strong Buy to Outperform | 2/20/2024 |
Related Tickers
GH Guardant Health, Inc.
17.47
+1.81%
EXAS Exact Sciences Corporation
59.40
+1.04%
NEO NeoGenomics, Inc.
14.28
+3.10%
TWST Twist Bioscience Corporation
31.19
+0.35%
VCYT Veracyte, Inc.
19.53
+0.26%
IQV IQVIA Holdings Inc.
235.79
+0.77%
ILMN Illumina, Inc.
123.01
+1.62%
CDNA CareDx, Inc
7.70
+1.85%
QGEN Qiagen N.V.
41.54
+1.11%
ICLR ICON Public Limited Company
309.94
+3.29%